Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndr

– Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification –– Analysis of 72 patients treated in STK-001 clinical trials suggests that higher...

Related Keywords

United Kingdom ,Massachusetts ,United States ,Orlando ,Florida ,Bedford ,Cambridge ,Cambridgeshire ,American ,Helen Cross ,Joseph Sullivan ,Archana Desurkar ,Eric Rojas ,Barry Ticho ,Pediatric Epilepsy Center ,Stoke Therapeutics Inc ,Exchange Commission ,University Of California San Francisco ,International League Against Epilepsy ,Company Annual Report On Form ,Nasdaq ,Augmentation Of Nuclear Gene Output ,American Epilepsy Society ,Stoke Therapeutics ,Meeting December ,Chief Medical Officer ,California San Francisco ,History Study ,Dravet Syndrome Ages ,Label Extension ,Month Analysis ,Observational Study ,Investigate Cognition ,Dravet Syndrome ,California San ,Kingdom Investigating Safety ,Drug Exposure ,Antisense Oligonucleotide ,Childhood Epilepsy ,Developmental Neuroscience Programme ,Child Health ,Honorary Consultant ,Paediatric Neurology ,International League Against ,Open Label Extension ,Previously Participated ,Consultant Paediatric Neurologist ,Sheffield Children ,Hospital National Health Service Foundation ,Dosing Regimens ,Senior Vice President ,Clinical Pharmacology ,Targeted Augmentation ,Nuclear Gene Output ,Private Securities Litigation Reform Act ,Annual Report ,Investor Contacts ,Investor Relations ,